Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
The latest update is out from Medicenna Therapeutics Corp ( (TSE:MDNA) ).
Medicenna Therapeutics announced that its President and CEO, Dr. Fahar Merchant, will participate in the ROTH 4th Annual Healthcare Opportunities Conference in New York City. This event will provide Medicenna with the opportunity to engage with institutional investors through 1-on-1 and small group meetings, potentially enhancing its visibility and investor relations within the healthcare sector.
The most recent analyst rating on (TSE:MDNA) stock is a Buy with a C$2.50 price target. To see the full list of analyst forecasts on Medicenna Therapeutics Corp stock, see the TSE:MDNA Stock Forecast page.
Spark’s Take on TSE:MDNA Stock
According to Spark, TipRanks’ AI Analyst, TSE:MDNA is a Neutral.
Medicenna Therapeutics Corp. receives a moderate overall score, reflecting its financial challenges and reliance on financing. However, positive results from clinical trials and promising preclinical data provide notable upside potential. Technical indicators are neutral, offering a balanced view of near-term stock performance. Valuation highlights the speculative nature typical of biotech stocks, while recent corporate events significantly bolster future growth prospects.
To see Spark’s full report on TSE:MDNA stock, click here.
More about Medicenna Therapeutics Corp
Medicenna Therapeutics Corp is a clinical-stage immunotherapy company focused on developing novel, highly selective versions of IL-2, IL-4, and IL-13 Superkines, as well as first-in-class Empowered Superkines. Their products, such as the long-acting IL-2 Superkine MDNA11 and the IL-4 Empowered Superkine bizaxofusp, are aimed at treating cancer and autoimmune diseases. The company has received FastTrack and Orphan Drug status from the FDA for some of its therapies and is working on enhancing Superkines to treat immunologically ‘cold’ tumors.
Average Trading Volume: 35,146
Technical Sentiment Signal: Sell
Current Market Cap: C$68.04M
For a thorough assessment of MDNA stock, go to TipRanks’ Stock Analysis page.